Novel antibiotics for the treatment of Staphylococcus aureus

Expert Review of Clinical Pharmacology

Volumn 2, Issue 6, 2009, Pages 661-672

  Ohlsen, Knut ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Antibiotic resistance; MRSA; Novel antibacterials; Staphylococcus aureus

Indexed keywords

ANTIBIOTIC AGENT; AZTREONAM; CEFTAROLINE; CEFTOBIPROLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DELAFLOXACIN; ICLAPRIM; LINEZOLID; METICILLIN; ORITAVANCIN; OXAZOLIDINONE DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RADEZOLID; RX 1741; RX 3341; TEICOPLANIN; TELAVANCIN; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN; ZEFTERA; ZEVEN; ZYVOX ID;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIAL GENOME; BACTERIAL PNEUMONIA; BACTERIAL SKIN DISEASE; BLOODSTREAM INFECTION; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; FASCIITIS; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NAUSEA; NONHUMAN; OPTIC NERVE DISEASE; PERIPHERAL NEUROPATHY; REVIEW; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION; TASTE DISORDER; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VOMITING;

EID: 70549104644     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/ecp.09.26     Document Type: Review

References (98)

1. Garau J, Bouza E, Chastre J, Gudiol F, Harbarth S. Management of methicillinresistant Staphylococcus aureus infections. Clin. Microbiol. Infect. 15, 125-136 (2009).
2. Gordon RJ, Lowy FD. Pathogenesis of methicillin-resistant Staphylococcus aureus infection. Clin. Infect. Dis. 46(Suppl. 5), S350-S359 (2008).
3. Diep BA, Otto M. The role of virulence determinants in community-associated MRSA pathogenesis. Trends Microbiol. 16, 361-369 (2008). • Review data on the role of specific virulence factors such as exotoxins and metabolic functions in pathogenesis of CA-MRSA.
4. Lowy FD. Staphylococcus aureus infections. N. Engl. J. Med. 339, 520-532 (1998).
5. National nosocomial infections surveillance (NNIS) system report, data summary from January 1992 through June 2004 issued October 2004. Am. J. Infect. Control 32, 470-485 (2004).
6. Tiemersma EW, Bronzwaer SL, Lyytikainen O et al. Methicillin-resistant Staphylococcus aureus in Europe, 1999-2002. Emerg. Infect. Dis. 10, 1627-1634 (2004).
7. David MZ, Rudolph KM, Hennessy TW, Boyle-Vavra S, Daum RS. Molecular epidemiology of methicillin-resistant Staphylococcus aureus, rural southwestern Alaska. Emerg. Infect. Dis. 14, 1693-1699 (2008).
8. Chambers HF. Community-associated MRSA-resistance and virulence converge. N. Engl. J. Med. 352, 1485-1487 (2005).
9. Diep BA, Sensabaugh GF, Somboona NS, Carleton HA, Perdreau-Remington F. Widespread skin and soft-tissue infections due to two methicillin-resistant Staphylococcus aureus strains harboring the genes for Panton-Valentine leucocidin. J. Clin. Microbiol. 42, 2080-2084 (2004). (Pubitemid 38637826)
10. Kazakova SV, Hageman JC, Matava M et al. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N. Engl. J. Med. 352, 468-475 (2005). (Pubitemid 40175973)
11. Bratu S, Eramo A, Kopec R et al. Community-associated methicillinresistant Staphylococcus aureus in hospital nursery and maternity units. Emerg. Infect. Dis. 11, 808-813 (2005). (Pubitemid 40720839)
12. Maree CL, Daum RS, Boyle-Vavra S, Matayoshi K, Miller LG. Communityassociated methicillin-resistant Staphylococcus aureus isolates causing healthcare-associated infections. Emerg. Infect. Dis. 13, 236-242 (2007). (Pubitemid 46193166)
13. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillinresistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin. Infect. Dis. 36, 53-59 (2003). (Pubitemid 36099097)
14. Shurland S, Zhan M, Bradham DD, Roghmann MC. Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillinsusceptible Staphylococcus aureus. Infect. Control Hosp. Epidemiol. 28, 273-279 (2007). (Pubitemid 46480725)
15. Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect. Control Hosp. Epidemiol. 26, 166-174 (2005). (Pubitemid 40445022)
16. Zahar JR, Clech C, Tafflet M et al. Is methicillin resistance associated with a worse prognosis in Staphylococcus aureus ventilator-associated pneumonia? Clin. Infect. Dis. 41, 1224-1231 (2005). (Pubitemid 41532663)
17. Engemann JJ, Carmeli Y, Cosgrove SE et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin. Infect. Dis. 36, 592-598 (2003). (Pubitemid 36259564)
18. Klevens RM, Morrison MA, Nadle J et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298, 1763-1771 (2007). • Detailed analysis of different aspects of methicillin-resistant Staphylococcus aureus infections. (Pubitemid 47598444)
19. Chang S, Sievert DM, Hageman JC et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N. Engl. J. Med. 348, 1342-1347 (2003). (Pubitemid 36384101)
20. Witte W, Cuny C, Klare I, Nubel U, Strommenger B, Werner G. Emergence and spread of antibiotic-resistant Gram-positive bacterial pathogens. Int. J. Med. Microbiol. 298, 365-377 (2008).
21. Ohlsen K, Lorenz U. Novel targets for antibiotics in Staphylococcus aureus. Future Microbiol. 2, 655-666 (2007).
22. Martins A, Cunha Mde L. Methicillin resistance in Staphylococcus aureus and coagulase-negative staphylococci: epidemiological and molecular aspects. Microbiol. Immunol. 51, 787-795 (2007). (Pubitemid 47450475)
23. Ito T, Katayama Y, Asada K et al. Structural comparison of three types of staphylococcal cassette chromosome mec integrated in the chromosome in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 45, 1323-1336 (2001). (Pubitemid 32374098)
24. Deurenberg RH, Vink C, Kalenic S, Friedrich AW, Bruggeman CA, Stobberingh EE. The molecular evolution of methicillin-resistant Staphylococcus aureus. Clin. Microbiol. Infect. 13, 222-235 (2007). (Pubitemid 46603352)
25. Hiramatsu K, Katayama Y, Yuzawa H, Ito T. Molecular genetics of methicillinresistant Staphylococcus aureus. Int. J. Med. Microbiol. 292, 67-74 (2002). (Pubitemid 34842177)
26. Couto I, de Lencastre H, Severina E et al. Ubiquitous presence of a mecA homologue in natural isolates of Staphylococcus sciuri. Microb. Drug Resist. 2, 377-391 (1996). (Pubitemid 27030504)
27. Lowy FD. Antimicrobial resistance: the example of Staphylococcus aureus. J. Clin. Invest. 111, 1265-1273 (2003).
28. Projan SJ. Why is big Pharma getting out of antibacterial drug discovery? Curr. Opin. Microbiol. 6, 427-430 (2003). • Critcal review on reasons for strategic decisions of pharmaceutical industry.
29. Coates AR, Hu Y. Novel approaches to developing new antibiotics for bacterial infections. Br. J. Pharmacol. 152, 1147-1154 (2007). (Pubitemid 350242433)
30. Raes J, Korbel JO, Lercher MJ, von Mering C, Bork P. Prediction of effective genome size in metagenomic samples. Genome Biol. 8, R10 (2007). (Pubitemid 351910992)
31. Capparelli R, Parlato M, Borriello G, Salvatore P, Iannelli D. Experimental phage therapy against Staphylococcus aureus in mice. Antimicrob. Agents Chemother. 51, 2765-2773 (2007). (Pubitemid 47206211)
32. Fischetti VA. Bacteriophage lysins as effective antibacterials. Curr. Opin. Microbiol. 11, 393-400 (2008).
33. Ippolito JA, Kanyo ZF, Wang D et al. Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit. J. Med. Chem. 51, 3353-3356 (2008). (Pubitemid 351874992)
34. Micek ST. Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. 45(Suppl. 3), S184-S190 (2007).
35. French GL. What's new and not so new on the antimicrobial horizon? Clin. Microbiol. Infect. 14(Suppl. 6), 19-29 (2008).
36. De Cock E, Krueger WA, Sorensen S et al. Cost-effectiveness of linezolid vs vancomycin in suspected methicillinresistant Staphylococcus aureus nosocomial pneumonia in Germany. Infection 37, 123-132 (2009).
37. Itani KM, Weigelt J, Li JZ, Duttagupta S. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). Int. J. Antimicrob. Agents 26, 442-448 (2005). (Pubitemid 41635493)
38. Kohno S, Yamaguchi K, Aikawa N et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J. Antimicrob. Chemother. 60, 1361-1369 (2007). (Pubitemid 350168334)
39. Weigelt J, Kaafarani HM, Itani KM, Swanson RN. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am. J. Surg. 188, 760-766 (2004).
40. Shorr AF, Kunkel MJ, Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J. Antimicrob. Chemother. 56, 923-929 (2005). (Pubitemid 41631919)
41. Garazzino S, De Rosa FG, Bargiacchi O, Audagnotto S, Maiello A, Di Perri G. Haematological safety of long-term therapy with linezolid. Int. J. Antimicrob. Agents 29, 480-483 (2007). (Pubitemid 46349598)
42. Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin. Infect. Dis. 42, 1578-1583 (2006). (Pubitemid 43752646)
43. Stevens DL, Ma Y, Salmi DB, McIndoo E, Wallace RJ, Bryant AE. Impact of antibiotics on expression of virulenceassociated exotoxin genes in methicillinsensitive and methicillin-resistant Staphylococcus aureus. J. Infect. Dis. 195, 202-211 (2007). (Pubitemid 46080052)
44. Jones RN, Ross JE, Castanheira M, Mendes RE. United States resistance surveillance results for linezolid (LEADER Program for 2007). Diagn. Microbiol. Infect. Dis. 62, 416-426 (2008).
45. Meka VG, Gold HS. Antimicrobial resistance to linezolid. Clin. Infect. Dis. 39, 1010-1015 (2004).
46. Meka VG, Gold HS, Cooke A et al. Reversion to susceptibility in a linezolidresistant clinical isolate of Staphylococcus aureus. J. Antimicrob. Chemother. 54, 818-820 (2004). (Pubitemid 39386737)
47. Meka VG, Pillai SK, Sakoulas G et al. Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J. Infect. Dis. 190, 311-317 (2004). (Pubitemid 38951971)
48. Kehrenberg C, Aarestrup FM, Schwarz S. IS21-558 insertion sequences are involved in the mobility of the multiresistance gene cfr. Antimicrob. Agents Chemother. 51, 483-487 (2007). (Pubitemid 46185264)
49. Kehrenberg C, Schwarz S. Distribution of florfenicol resistance genes fexA and cfr among chloramphenicol-resistant Staphylococcus isolates. Antimicrob. Agents Chemother. 50, 1156-1163 (2006).
50. Mendes RE, Deshpande LM, Castanheira M, DiPersio J, Saubolle MA, Jones RN. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob. Agents Chemother. 52, 2244-2246 (2008). (Pubitemid 351758569)
51. Long KS, Poehlsgaard J, Kehrenberg C, Schwarz S, Vester B. The Cfr rRNA methyltransferase confers resistance to Phenicols, Lincosamides, Oxazolidinones, Pleuromutilins, and Streptogramin A antibiotics. Antimicrob. Agents Chemother. 50, 2500-2505 (2006). (Pubitemid 43993192)
52. Kehrenberg C, Cuny C, Strommenger B, Schwarz S, Witte W. Methicillin-resistant and -susceptible Staphylococcus aureus strains of clonal lineages ST398 and ST9 from swine carry the multidrug resistance gene cfr. Antimicrob. Agents Chemother. 53, 779-781 (2009).
53. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant Gram-positive pathogens. Clin. Infect. Dis. 38, 994-1000 (2004).
54. Jevitt LA, Smith AJ, Williams PP, Raney PM, McGowan JE Jr, Tenover FC. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycinintermediate Staphylococcus aureus and vancomycin-resistant Enterococcus faecium. Microb. Drug Resist. 9, 389-393 (2003).
55. Steenbergen JN, Alder J, Thorne GM, Tally FP. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J. Antimicrob. Chemother. 55, 283-288 (2005). (Pubitemid 40425449)
56. Huang YT, Liao CH, Teng LJ, Hsueh PR. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan. Clin. Microbiol. Infect. 14, 124-129 (2008).
57. Julian K, Kosowska-Shick K, Whitener C et al. Characterization of a daptomycinnonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis. Antimicrob. Agents Chemother. 51, 3445-3448 (2007). (Pubitemid 350067576)
58. Patel JB, Jevitt LA, Hageman J, McDonald LC, Tenover FC. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin. Infect. Dis. 42, 1652-1653 (2006). (Pubitemid 43752657)
59. Cui L, Tominaga E, Neoh HM, Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50, 1079-1082 (2006). (Pubitemid 43327815)
60. Fowler VG, Jr., Boucher HW, Corey GR et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 355, 653-665 (2006). • Important clinical study to evaluate efficacy of daptomycin compared with standard therapy for severe Staphylococcus aureus infections.
61. Lalani T, Boucher HW, Cosgrove SE et al. Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia. J. Antimicrob. Chemother. 61, 177-182 (2008).
62. Friedman L, Alder JD, Silverman JA. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob. Agents Chemother. 50, 2137-2145 (2006). (Pubitemid 43807536)
63. Boucher HW, Sakoulas G. Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin. Infect. Dis. 45, 601-608 (2007). (Pubitemid 47328642)
64. Sader HS, Jones RN, Dowzicky MJ, Fritsche TR. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn. Microbiol. Infect. Dis. 52, 203-208 (2005).
65. Livermore DM. Tigecycline: what is it, and where should it be used? J. Antimicrob. Chemother. 56, 611-614 (2005).
66. Pillar CM, Draghi DC, Dowzicky MJ, Sahm DF. In vitro activity of tigecycline against Gram-positive and Gram-negative pathogens as evaluated by broth microdilution and Etest. J. Clin. Microbiol. 46, 2862-2867 (2008).
67. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind Phase 3 comparison studies with vancomycin-aztreonam. Clin. Infect. Dis. 41(Suppl. 5), S341-S353 (2005). (Pubitemid 41170381)
68. Florescu I, Beuran M, Dimov R et al. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillinresistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. J. Antimicrob. Chemother. 62(Suppl. 1), I17-I28 (2008).
69. Sacchidanand S, Penn RL, Embil JM et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a Phase 3, randomized, double-blind trial. Int. J. Infect. Dis. 9, 251-261 (2005). (Pubitemid 41196869)
70. Swoboda S, Ober M, Hainer C et al. Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit. J. Antimicrob. Chemother. 61, 729-733 (2008). (Pubitemid 351321153)
71. Gales AC, Sader HS, Fritsche TR. Tigecycline activity tested against 11808 bacterial pathogens recently collected from US medical centers. Diagn. Microbiol. Infect. Dis. 60, 421-427 (2008).
72. Pachon-Ibanez ME, Jimenez-Mejias ME, Pichardo C, Llanos AC, Pachon J. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob. Agents Chemother. 48, 4479-4481 (2004). (Pubitemid 39434923)
73. Nichols RL, Graham DR, Barriere SL et al. Treatment of hospitalized patients with complicated Gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/ dalfopristin versus cefazolin, oxacillin or vancomycin: Synercid Skin and Skin Structure Infection group. J. Antimicrob. Chemother. 44, 263-273 (1999).
74. Chambers HF. Ceftobiprole: in-vivo profile of a bactericidal cephalosporin. Clin Microbiol. Infect. 12(Suppl. 2), 17-22 (2006).
75. Fritsche TR, Sader HS, Jones RN. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006). Diagn. Microbiol. Infect. Dis. 61, 86-95 (2008).
76. Pope SD, Roecker AM. Dalbavancin: a novel lipoglycopeptide antibacterial. Pharmacotherapy 26,908-918 (2006).
77. Bailey J, Summers KM. Dalbavancin: a new lipoglycopeptide antibiotic. Am. J. Health Syst. Pharm. 65, 599-610 (2008).
78. Biedenbach DJ, Bell JM, Sader HS, Turnidge JD, Jones RN. Activities of dalbavancin against a worldwide collection of 81,673 Gram-positive bacterial isolates. Antimicrob. Agents Chemother. 53, 1260-1263 (2009).
79. Biedenbach DJ, Jones RN. Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007). Diagn. Microbiol. Infect. Dis. 64, 177-184 (2009).
80. Gales AC, Sader HS, Jones RN. Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres. Clin. Microbiol. Infect. 11, 95-100 (2005).
81. Attwood RJ, LaPlante KL. Telavancin: a novel lipoglycopeptide antimicrobial agent. Am. J. Health Syst. Pharm. 64, 2335-2348 (2007).
82. Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF. Comparative surveillance study of telavancin activity against recently collected Gram-positive clinical isolates from across the United States. Antimicrob. Agents Chemother. 52, 2383-2388 (2008). (Pubitemid 351915666)
83. Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-2005 Prospective European Surveillance Initiative. J. Antimicrob. Chemother. 62, 116-121 (2008).
84. Stryjewski ME, Graham DR, Wilson SE et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by Gram-positive organisms. Clin. Infect. Dis. 46, 1683-1693 (2008).
85. Crandon J, Nicolau DP: Oritavancin. a potential weapon in the battle against serious Gram-positive pathogens. Future Microbiol. 3, 251-263 (2008). (Pubitemid 352003135)
86. Zhanel GG, Sniezek G, Schweizer F et al. Ceftaroline: A novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus. Drugs 69, 809-831 (2009).
87. Kanafani ZA, Corey GR. Ceftaroline: a cephalosporin with expanded Grampositive activity. Future Microbiol. 4, 25-33 (2009).
88. Laue H, Weiss L, Bernardi A, Hawser S, Lociuro S, Islam K. In vitro activity of the novel diaminopyrimidine, iclaprim, in combination with folate inhibitors and other antimicrobials with different mechanisms of action. J. Antimicrob. Chemother. 60, 1391-1394 (2007). (Pubitemid 350168340)
89. Schneider P, Hawser S, Islam K. Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorg. Med. Chem. Lett. 13, 4217-4221 (2003). (Pubitemid 37410316)
90. Krievins D, Brandt R, Hawser S, Hadvary P, Islam K. Multicenter, randomized study of the efficacy and safety of intravenous iclaprim in complicated skin and skin structure infections. Antimicrob. Agents Chemother. 53, 2834-2840 (2009).
91. Lawrence L, Danese P, DeVito J, Franceschi F, Sutcliffe J. In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. Antimicrob. Agents Chemother. 52, 1653-1662 (2008). (Pubitemid 351614657)
92. Leonard SN, Cheung CM, Rybak MJ. Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospitalassociated methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 52, 2974-2976 (2008).
93. Traczewski MM, Katz BD, Steenbergen JN, Brown SD. Inhibitory and bactericidal activities of daptomycin, vancomycin, and teicoplanin against methicillin-resistant Staphylococcus aureus isolates collected from 1985 to 2007. Antimicrob. Agents Chemother. 53, 1735-1738 (2009).
94. Noviello S, Ianniello F, Esposito S. In vitro activity of LY333328 (oritavancin) against Gram-positive aerobic cocci and synergy with ciprofloxacin against enterococci. J. Antimicrob. Chemother. 48, 283-286 (2001). (Pubitemid 32755293)
95. Patel R, Rouse MS, Piper KE, Cockerill FR, 3rd, Steckelberg JM. In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillinresistant Streptococcus pneumoniae. Diagn. Microbiol. Infect. Dis. 30, 89-92 (1998). (Pubitemid 28102862)
96. Business wire www.businesswire.com/portal/site/ pfizer/?ndmViewId=news- view&newsId=2 00809&newsLang=en).
97. Rib-X pharmaceuticals www.rib-x.com/news-and-events/ release-2009-01-26)
98. European committee on antimicrobial susceptibility testing www.srga.org/eucastwt/MICTAB/index. html